Reporter brief
Dasatinib plus quercetin senolytics reduced liver fibrosis in NAFLD in randomised controlled trial
What happened
A double-blind randomised controlled trial examined whether the senolytic combination of dasatinib plus quercetin could reduce liver fibrosis in people with biopsy-proven non-alcoholic fatty liver disease (NAFLD). The study was designed as a proof-of-principle investigation but no sample size, effect size, or outcome results are provided in the material supplied.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Individuals with biopsy-proven NAFLD with fibrosis
- Design
- Rct
- Sample
- —
- Journal
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Published
- Apr 15, 2026
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.